TIDMFUM
RNS Number : 1058O
Futura Medical PLC
05 October 2021
Directors' / PDMR Dealing and Grant of Options
5 October 2021
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a
pharmaceutical company developing a portfolio of innovative
products based on its proprietary, transdermal DermaSys(R) drug
delivery technology currently focused on sexual health and pain,
today announces that on 4 October 2021 it made its annual grant of
options over a total of 1,654,800 ordinary shares of 0.2p each in
the Company ("Ordinary Shares") to employees and Directors, of
which 858,000 options were granted to Directors and PDMRs as
detailed below.
Total number
Number of options Total number
of options Exercise held following of Ordinary
Director granted price Exercise period notification Shares held
----------- ----------- -------- --------------- --------------- ------------
1 Oct 2023 - 30
J H Barder 330,000 37.9p Sep 2028 1,880,000 1,210,972
1 Oct 2023 - 30
A Hildreth 264,000 37.9p Sept 2028 904,000 142,857
1 Oct 2023 - 30
K W James 264,000 37.9p Sept 2028 1,304,000 299,581
Of the total 1,654,800 options, 1,155,122 were granted under the
Futura Medical plc Enterprise Management Incentive Scheme, and
499,678 were granted under the unapproved scheme.
The main vesting condition of the options is that the
Director/PDMR/employee remains employed with the Company as at the
date of exercise. Further disclosures are contained in the tables
below.
S
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Broker:
Liberum
Richard Lindley/ Euan Brown/ Kane Collings
Tel: +44 (0) 203 100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction (ED) through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application. MED3000 is CE marked in Europe
and the UK as a clinically proven topical treatment for adult men
with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name James Barder
------------------------------- --------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------- --------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Futura Medical plc
------------------------------- --------------------------------------
b) LEI 21380053QLT46UNV2303
------------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.2 pence each
financial instrument,
type of instrument
GB0033278473
Identification code
------------------------------- --------------------------------------
b) Nature of the transaction Grant of options over Ordinary Shares
------------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Exercise price
of
37.90 pence 330,000
----------
------------------------------- --------------------------------------
d) Aggregated information N/A single transaction
- Aggregated volume
- Price
------------------------------- --------------------------------------
e) Date of the transaction 4 October 2021
------------------------------- --------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- --------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Angela Hildreth
------------------------------- --------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status Finance Director and
Chief Operating Officer
------------------------------- --------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Futura Medical plc
------------------------------- --------------------------------------
b) LEI 21380053QLT46UNV2303
------------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.2 pence each
financial instrument,
type of instrument
GB0033278473
Identification code
------------------------------- --------------------------------------
b) Nature of the transaction Grant of options over Ordinary Shares
------------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Exercise price
of
37.90 pence 264,000
----------
------------------------------- --------------------------------------
d) Aggregated information N/A single transaction
- Aggregated volume
- Price
------------------------------- --------------------------------------
e) Date of the transaction 4 October 2021
------------------------------- --------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- --------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Ken James
------------------------------- --------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status Executive Director
and Head of R&D
------------------------------- --------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Futura Medical plc
------------------------------- --------------------------------------
b) LEI 21380053QLT46UNV2303
------------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.2 pence each
financial instrument,
type of instrument
GB0033278473
Identification code
------------------------------- --------------------------------------
b) Nature of the transaction Grant of options over Ordinary Shares
------------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Exercise price
of
37.90 pence 264,000
----------
------------------------------- --------------------------------------
d) Aggregated information N/A single transaction
- Aggregated volume
- Price
------------------------------- --------------------------------------
e) Date of the transaction 4 October 2021
------------------------------- --------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- --------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFIEIVLEIIL
(END) Dow Jones Newswires
October 05, 2021 11:05 ET (15:05 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2024 to May 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From May 2023 to May 2024